HCW Competitors
| HCWB Stock | USD 0.99 0.06 5.71% |
HCW Biologics vs Aptevo Therapeutics Correlation
Very poor diversification
The correlation between HCW Biologics and APVO is 0.88 (i.e., Very poor diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding HCW Biologics and APVO in the same portfolio, assuming nothing else is changed.
Moving together with HCW Stock
Moving against HCW Stock
| 0.87 | DSGN | Design Therapeutics | PairCorr |
| 0.82 | IMMP | Immutep Ltd ADR | PairCorr |
| 0.71 | ENGN | enGene Holdings Common | PairCorr |
| 0.68 | KYTX | Kyverna Therapeutics | PairCorr |
| 0.62 | 63E | ONWARD MEDICAL BV | PairCorr |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of HCW Biologics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
HCW Biologics Competition Correlation Matrix
Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between HCW Biologics and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of HCW and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of HCW Biologics does not affect the price movement of the other competitor.
High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between HCW Stock performing well and HCW Biologics Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze HCW Biologics' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| INAB | 5.05 | 0.12 | 0.03 | 0.09 | 5.06 | 14.29 | 37.96 | |||
| NRSN | 4.33 | (0.22) | 0.00 | (5.73) | 0.00 | 12.82 | 34.62 | |||
| ADIL | 73.41 | 32.12 | 1.69 | 0.48 | 11.60 | 6.67 | 2,483 | |||
| ACXP | 4.44 | (1.17) | 0.00 | (0.94) | 0.00 | 10.84 | 49.19 | |||
| RNAZ | 4.20 | (0.35) | 0.00 | (1.00) | 0.00 | 8.35 | 34.47 | |||
| CELZ | 4.04 | (0.80) | 0.00 | (0.45) | 0.00 | 8.61 | 23.26 | |||
| BCDA | 2.62 | (0.15) | 0.00 | (0.18) | 0.00 | 5.93 | 17.38 | |||
| BCLI | 3.63 | (0.07) | 0.00 | 0.14 | 0.00 | 9.09 | 24.01 | |||
| APRE | 3.88 | (1.10) | 0.00 | (0.56) | 0.00 | 4.40 | 46.26 | |||
| APVO | 4.60 | (2.10) | 0.00 | (2.55) | 0.00 | 6.67 | 43.37 |
Cross Equities Net Income Analysis
Compare HCW Biologics and related stocks such as In8bio Inc, Neurosense Therapeutics, and Adial Pharmaceuticals Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| INAB | (2.1 M) | (2.1 M) | (2.1 M) | (2.1 M) | (2.1 M) | (2.1 M) | (2.1 M) | (2.1 M) | (2.1 M) | (5.1 M) | (8.6 M) | (14.7 M) | (27.4 M) | (30 M) | (30.4 M) | (27.4 M) | (26 M) |
| NRSN | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (2.8 M) | (4 M) | (12.3 M) | (10.1 M) | (10.2 M) | (9.2 M) | (9.6 M) |
| ADIL | (818 K) | (818 K) | (818 K) | (818 K) | (818 K) | (818 K) | (420.2 K) | (1.1 M) | (11.6 M) | (8.6 M) | (10.9 M) | (19.4 M) | (12.7 M) | (7 M) | (13.2 M) | (11.9 M) | (12.5 M) |
| ACXP | (5.9 M) | (5.9 M) | (5.9 M) | (5.9 M) | (5.9 M) | (5.9 M) | (5.9 M) | (5.9 M) | (5.9 M) | (5.9 M) | (4.6 M) | (12.7 M) | (12.1 M) | (14.6 M) | (14.1 M) | (12.7 M) | (13.3 M) |
| RNAZ | (453.4 K) | (453.4 K) | (453.4 K) | (453.4 K) | (453.4 K) | (453.4 K) | (453.4 K) | (453.4 K) | (453.4 K) | (607.2 K) | (2.3 M) | (6.8 M) | (17.6 M) | (18.5 M) | (16.8 M) | (15.1 M) | (14.3 M) |
| CELZ | 1.4 K | (24.1 K) | (25.6 K) | (27.3 K) | (28 K) | (30.8 K) | (766.1 K) | (2.7 M) | (13.7 M) | (8.5 M) | (36.3 M) | 19.2 M | (10.1 M) | (5.3 M) | (5.5 M) | (4.9 M) | (5.2 M) |
| BCDA | 135.6 K | 9.7 M | 305 K | 19 K | 234 K | 322 K | (10.3 M) | (12.3 M) | (14 M) | (14.7 M) | (15 M) | (12.6 M) | (11.9 M) | (11.6 M) | (7.9 M) | (7.2 M) | (6.8 M) |
| BCLI | (25.6 K) | (3.9 M) | (3.4 M) | (4.9 M) | (9.2 M) | (8.5 M) | (5 M) | (5 M) | (13.9 M) | (23.3 M) | (31.8 M) | (24.5 M) | (23.7 M) | (17.2 M) | 11.6 M | 10.5 M | 11 M |
| APRE | (3.5 M) | (254 K) | (254 K) | (436.2 K) | (15.2 M) | (15.2 M) | (15.2 M) | (15.2 M) | (15.5 M) | (28.1 M) | (53.9 M) | (36.5 M) | (112.7 M) | (14.3 M) | (13 M) | (11.7 M) | (12.2 M) |
| APVO | (53.3 M) | (53.3 M) | (53.3 M) | (53.3 M) | (51.1 M) | (59.3 M) | (112.4 M) | 7 M | (53.7 M) | (44.7 M) | (17.8 M) | (27.3 M) | 8 M | (17.4 M) | (24.1 M) | (27.7 M) | (29.1 M) |
HCW Biologics and related stocks such as In8bio Inc, Neurosense Therapeutics, and Adial Pharmaceuticals Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in HCW Biologics financial statement analysis. It represents the amount of money remaining after all of HCW Biologics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.HCW Biologics Competitive Analysis
The better you understand HCW Biologics competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, HCW Biologics' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across HCW Biologics' competition over several years is one of the best ways to analyze its investment potential.| Better Than Average | Worse Than Peers | View Performance Chart |
HCW Biologics Competition Performance Charts
Five steps to successful analysis of HCW Biologics Competition
HCW Biologics' competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by HCW Biologics in relation to its competition. HCW Biologics' competition analysis typically involves several steps, including:- Identifying the key players in the market: This involves identifying the major competitors of HCW Biologics in the market, both direct and indirect, as well as new entrants and disruptive technologies.
- Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
- Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact HCW Biologics' competitive landscape.
- Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to HCW Biologics, and developing a strategy to address them.
- Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Complement your HCW Biologics position
In addition to having HCW Biologics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Munis Funds Thematic Idea Now
Munis Funds
Funds or Etfs that invest in fixed income securities issued by states, cities, and towns as well as other public entities. The Munis Funds theme has 39 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Munis Funds Theme or any other thematic opportunities.
| View All Next | Launch |
Check out HCW Biologics Correlation with its peers. For information on how to trade HCW Stock refer to our How to Trade HCW Stock guide.You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of HCW Biologics. Market participants price HCW higher when confident in its future expansion prospects. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive HCW Biologics assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share (16.41) | Revenue Per Share | Quarterly Revenue Growth (0.99) | Return On Assets | Return On Equity |
Investors evaluate HCW Biologics using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating HCW Biologics' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. External factors like market trends, sector rotation, and investor psychology can cause HCW Biologics' market price to deviate significantly from intrinsic value.
Please note, there is a significant difference between HCW Biologics' value and its price as these two are different measures arrived at by different means. Investors typically determine if HCW Biologics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Conversely, HCW Biologics' market price signifies the transaction level at which participants voluntarily complete trades.